Yuchao Jiang

Principal Scientist of Antibody Engineering, Founder @ Imperial College London

About

I am passionate about combining mechanistic research with clinical translation, and developing novel immunotherapies for mutation-specific or tissue-specific targets. I have co-founded Genehan Biomed, a biotech company that focuses on next-generation cell therapies. There, I led the discovery and engineering of novel CAR-T, TCR, and bispecific antibodies for various indications. Previously, I was the head of antibody discovery at HRAIN Biotechnology, where I established and optimized platforms for the discovery and engineering of monoclonal antibodies for CAR-T development. I also founded Pigentech Lab, a laboratory that provides services and solutions for biologics discovery and development. I have multiple patents and publications in the field of antibody engineering and neoantigen and TCR identification. My core competencies include antibody engineering, biologics discovery, neoantigen and TCR identification, genetic methods, and Linux. I am committed to finding innovative and effective solutions for unmet medical needs, and collaborating with other researchers and clinicians to advance the field of immunotherapy.

Country

United Kingdom

City

London

Industry

Research

Skill

Genome Sequencing, Genotyping, Epigenetics, In Vivo, Statistical Modeling, incuCyte, FACS, Neoantigen & TCR identification, Linux, 新药发现, Python, antibody discovery, antibody engineering, phage display, protein expression and purification, genome editing, assay development, R 语言, single B cell sequencing

Experience

Principal Scientist of Antibody Engineering, Founder

Pigentech Lab Limited

2016-1 - 2023-7 · 7 yrs 7 mos

Minhang District, Shanghai, China

Platforms for the discovery and engineering of novel monoclonal, bispecific and multispecific antibodies, immunocytokines and other biologics.

Director of Antibody Discovery

LongBio

2021 - 2022 · 1 yr

Under the mentorship of Dr. Bill Nai-Chau Sun, spearheaded the de novo establishment of a high-throughput single B-cell antibody discovery platform.

Head of Antibody Discovery

HRAIN BIOTECHNOLOGY

2018-1 - 2020-2 · 2 yrs 2 mos

Shanghai

CAR-T, Antibody Discovery

Assistant Professor of Pharmacology

Chinese Academy of Sciences

2016-5 - 2018-6 · 2 yrs 2 mos

Pudong, Shanghai, China

Antibody Discovery and Engineering, Phage Display, ADC, Bispecific Antibody Development

Visiting Scholar

University of Chicago

2016-6 - 2016-12 · 7 mos

Chicago, Illinois, United States

Structure Biology, Antibody Discovery, Protein Engineering

Education

Imperial College London

Immunology

My PhD at Imperial College London focuses on engineering next-generation cancer immunotherapies by overcoming immune suppression, designing iTCR-based bispecific and trispecific antibodies, and developing novel CAR-iNKT cell therapies. Supervised by Prof. Anastasios Karadimitris, with advisory support from Prof. Jessica Strid and Prof. Nadia Guerra. 🔬 Research Focus: 1️⃣ Reversing Tumor Immune Suppression – Targeting the immune suppression axis to restore immune cell function and enhance CAR-T, TILs, NK, and γδT therapies. 2️⃣ Next-Gen iTCR Therapeutics – Engineering bispecific and trispecific antibodies to selectively activate iNKT cells, unlocking new immune pathways. 3️⃣ Optimized iNKT-CAR Design – Creating a novel CAR structure for iNKT cells, enhancing persistence, tumor killing, and infiltration beyond conventional CAR-T. I integrate cell engineering, antibody discovery, and immune modulation to drive next-generation cancer therapies.

Fudan University

Human/Medical Genetics

Supervised by Prof. Li Jin and Prof. Hongyan Wang. Authored two SCI-indexed papers (with an impact factor greater than 5) as the first author in the field of medical genetics.